188 related articles for article (PubMed ID: 30239650)
1. Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade.
Sherman KE; Abdel-Hameed E; Rouster SD; Shata MTM; Blackard JT; Safaie P; Kroner B; Preiss L; Horn PS; Kottilil S
Clin Infect Dis; 2019 May; 68(11):1911-1918. PubMed ID: 30239650
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients.
Abravanel F; Raymond S; Pambrun E; Winnock M; Bonnard P; Sogni P; Trimoulet P; Dabis F; Salmon-Ceron D; Izopet J;
PLoS One; 2012; 7(11):e50289. PubMed ID: 23226258
[TBL] [Abstract][Full Text] [Related]
3. Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy.
Bowler S; Siriwardhana C; Mitchell BI; D'Antoni ML; Ogata-Arakaki D; Souza S; Yee R; Gangcuangco LMA; Chow DC; Ndhlovu LC; Shikuma C
HIV Res Clin Pract; 2019; 20(4-5):123-129. PubMed ID: 32013805
[No Abstract] [Full Text] [Related]
4. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
[TBL] [Abstract][Full Text] [Related]
5. T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonists.
Vincent T; Portales P; Baillat V; de Boever CM; Le Moing V; Vidal M; Ducos J; Clot J; Reynes J; Corbeau P
J Acquir Immune Defic Syndr; 2005 Mar; 38(3):305-9. PubMed ID: 15735449
[TBL] [Abstract][Full Text] [Related]
6. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
Visseaux B; Charpentier C; Collin G; Bertine M; Peytavin G; Damond F; Matheron S; Lefebvre E; Brun-Vézinet F; Descamps D;
PLoS One; 2015; 10(8):e0134904. PubMed ID: 26247470
[TBL] [Abstract][Full Text] [Related]
7. CCR5+ T-Cells Homed to the Liver Exhibit Inflammatory and Profibrogenic Signatures in Chronic HIV/HCV-Coinfected Patients.
Shrivastava S; Kottilil S; Sherman KE; Masur H; Tang L
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696504
[TBL] [Abstract][Full Text] [Related]
8. The Enhanced Liver Fibrosis Index Predicts Hepatic Fibrosis Superior to FIB4 and APRI in HIV/HCV Infected Patients.
Abdel-Hameed EA; Rouster SD; Kottilil S; Sherman KE
Clin Infect Dis; 2021 Aug; 73(3):450-459. PubMed ID: 32459305
[TBL] [Abstract][Full Text] [Related]
9. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.
D'Antoni ML; Mitchell BI; McCurdy S; Byron MM; Ogata-Arakaki D; Chow D; Mehta NN; Boisvert WA; Lefebvre E; Shikuma CM; Ndhlovu LC; Baumer Y
J Leukoc Biol; 2018 Dec; 104(6):1241-1252. PubMed ID: 30088682
[TBL] [Abstract][Full Text] [Related]
10. Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score.
Swanson S; Ma Y; Scherzer R; Huhn G; French AL; Plankey MW; Grunfeld C; Rosenberg WM; Peters MG; Tien PC
J Infect Dis; 2016 Apr; 213(7):1079-86. PubMed ID: 26621911
[TBL] [Abstract][Full Text] [Related]
11. CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.
Blackard JT; Kong L; Rouster SD; Karns R; Horn PS; Kottilil S; Shata MT; Sherman KE
PLoS One; 2019; 14(10):e0224523. PubMed ID: 31661521
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis.
Tuyama AC; Hong F; Saiman Y; Wang C; Ozkok D; Mosoian A; Chen P; Chen BK; Klotman ME; Bansal MB
Hepatology; 2010 Aug; 52(2):612-22. PubMed ID: 20683959
[TBL] [Abstract][Full Text] [Related]
13. Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable.
Fätkenheuer G; Hoffmann C; Slim J; Rouzier R; Keung A; Li J; Treitel M; Sansone-Parsons A; Kasserra C; O'Mara E; Schürmann D
J Acquir Immune Defic Syndr; 2010 Jan; 53(1):78-85. PubMed ID: 19838130
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
[TBL] [Abstract][Full Text] [Related]
15. The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline.
Kramer VG; Hassounah S; Colby-Germinario SP; Oliveira M; Lefebvre E; Mesplède T; Wainberg MA
J Antimicrob Chemother; 2015 Mar; 70(3):750-6. PubMed ID: 25433008
[TBL] [Abstract][Full Text] [Related]
16. Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.
Rockstroh JK; Soriano V; Plonski F; Bansal M; Fätkenheuer G; Small CB; Asmuth DM; Pialoux G; Mukwaya G; Jagannatha S; Heera J; Pineda JA
HIV Clin Trials; 2015; 16(2):72-80. PubMed ID: 25923596
[TBL] [Abstract][Full Text] [Related]
17. CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia.
Wasmuth HE; Werth A; Mueller T; Berg T; Dietrich CG; Geier A; Schirin-Sokhan R; Gartung C; Lorenzen J; Matern S; Lammert F
J Mol Med (Berl); 2004 Jan; 82(1):64-9. PubMed ID: 14673528
[TBL] [Abstract][Full Text] [Related]
18. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation.
Kostrikis LG; Huang Y; Moore JP; Wolinsky SM; Zhang L; Guo Y; Deutsch L; Phair J; Neumann AU; Ho DD
Nat Med; 1998 Mar; 4(3):350-3. PubMed ID: 9500612
[TBL] [Abstract][Full Text] [Related]
19. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C.
Woitas RP; Ahlenstiel G; Iwan A; Rockstroh JK; Brackmann HH; Kupfer B; Matz B; Offergeld R; Sauerbruch T; Spengler U
Gastroenterology; 2002 Jun; 122(7):1721-8. PubMed ID: 12055576
[TBL] [Abstract][Full Text] [Related]
20. Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection.
Klibanov OM; Williams SH; Iler CA
Curr Opin Investig Drugs; 2010 Aug; 11(8):940-50. PubMed ID: 20721836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
